[HTML][HTML] Somatic alterations in mitochondrial DNA and mitochondrial dysfunction in gastric cancer progression

HC Lee, KH Huang, TS Yeh, CW Chi�- World Journal of�…, 2014 - ncbi.nlm.nih.gov
HC Lee, KH Huang, TS Yeh, CW Chi
World Journal of Gastroenterology: WJG, 2014ncbi.nlm.nih.gov
Energy metabolism reprogramming was recently identified as one of the cancer hallmarks.
One of the underlying mechanisms of energy metabolism reprogramming is mitochondrial
dysfunction caused by mutations in nuclear genes or mitochondrial DNA (mtDNA). In the
past decades, several types of somatic mtDNA alterations have been identified in gastric
cancer. However, the role of these mtDNA alterations in gastric cancer progression remains
unclear. In this review, we summarize recently identified somatic mtDNA alterations in�…
Abstract
Energy metabolism reprogramming was recently identified as one of the cancer hallmarks. One of the underlying mechanisms of energy metabolism reprogramming is mitochondrial dysfunction caused by mutations in nuclear genes or mitochondrial DNA (mtDNA). In the past decades, several types of somatic mtDNA alterations have been identified in gastric cancer. However, the role of these mtDNA alterations in gastric cancer progression remains unclear. In this review, we summarize recently identified somatic mtDNA alterations in gastric cancers as well as the relationship between these alterations and the clinicopathological features of gastric cancer. The causative factors and potential roles of the somatic mtDNA alterations in cancer progression are also discussed. We suggest that point mutations and mtDNA copy number decreases are the two most common mtDNA alterations that result in mitochondrial dysfunction in gastric cancers. The two primary mutation types (transition mutations and mononucleotide or dinucleotide repeat instability) imply potential causative factors. Mitochondrial dysfunction-generated reactive oxygen species may be involved in the malignant changes of gastric cancer. The search for strategies to prevent mtDNA alterations and inhibit the mitochondrial retrograde signaling will benefit the development of novel treatments for gastric cancer and other malignancies.
ncbi.nlm.nih.gov